Physiologically Based pharmacokinetic (PBPK) modeling for optimal dosage prediction of quinine co-administered with ritonavir-boosted lopinavir.
The co-formulated lopinavir/ritonavir significantly reduces quinine concentration in healthy volunteers due to potential drug-drug interactions (DDIs). However, DDIs information in malaria and HIV co-infected patients are lacking. The objective of the study was to apply physiologically-based pharmacokinetic modeling to predict optimal dosage regimens of quinine when co-administered with lopinavir/ritonavir in malaria and HIV co-infected patients with different conditions. The developed model was validated against literature. Model verification was evaluated using the accepted method. The verified PBPK models successfully predicted unbound quinine disposition when co-administered with lopinavir/ritonavir in co-infected patients with different conditions. Suitable dose adjustments to counteract with the DDIs have identified in patients with various situations, i.e., a 7-day course at 1800 mg TID in malaria patients with HIV infection, 648 mg BID in chronic renal failure, 648 mg TID in hepatic insufficiency except for severe hepatic insufficiency (324 mg BID), and 648 mg TID in CYP3A4 polymorphism.